• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年卵巢癌的手术治疗考虑因素。

Considerations in the surgical management of ovarian cancer in the elderly.

出版信息

Curr Treat Options Oncol. 2013 Mar;14(1):12-21. doi: 10.1007/s11864-012-0216-2.

DOI:10.1007/s11864-012-0216-2
PMID:23197271
Abstract

Elderly patients with advanced epithelial ovarian cancer present a complex treatment dilemma. On the one hand, patients can be treated with primary debulking surgery to achieve the ideal oncologic outcomes but at the expense of risk of surgical morbidity and mortality. On the other hand, they can be treated with alternative, less morbid approaches, reducing toxicity, but sacrificing the survival benefits of low residual disease by surgical cytoreduction. Retrospective studies have attempted to identify risk factors for poor surgical outcome. Although there is no consensus to define "elderly" or "frail," current evidence identifies age, performance status, nutritional status, and surgical complexity as major risk factors for surgical morbidity. Accepting the shortcomings of these retrospective data, candidates for primary debulking surgery can be assessed for risk of surgical morbidity. Age is likely a contributor to morbidity, particularly in the face of comorbid conditions. Clinicians should strive to treat elderly patients with a standard approach of primary debulking surgery and adjuvant chemotherapy when healthy and in the absence of other risk factors. Elderly patients with the following are poor surgical candidates and an alternative treatment approach should be considered: poor nutritional status (characterized by serum albumin <3.0 g/dL), or poor performance status (ASA ≥3), and stage IV disease. Several of these factors are modifiable by treating the underlying cancer. These patients should be treated with two to three cycles of neoadjuvant chemotherapy and reassessed for surgical debulking. Patients with improvement in their nutritional or performance status can undergo interval debulking with the goal to resect all visible disease.

摘要

老年晚期上皮性卵巢癌患者面临复杂的治疗困境。一方面,患者可以接受初次肿瘤细胞减灭术治疗,以达到理想的肿瘤学疗效,但要承担手术发病率和死亡率增加的风险。另一方面,患者也可以选择接受其他侵袭性较小的方法,降低毒性,但会牺牲手术减瘤带来的生存获益。回顾性研究试图确定手术结局不良的风险因素。尽管目前尚无定义“老年”或“虚弱”的共识,但现有证据表明,年龄、体能状态、营养状况和手术复杂性是手术发病率的主要危险因素。尽管这些回顾性数据存在局限性,但可以对接受初次肿瘤细胞减灭术的患者进行手术发病率风险评估。年龄可能是发病率的一个促成因素,尤其是在存在合并症的情况下。在患者健康且无其他风险因素的情况下,临床医生应努力采用初次肿瘤细胞减灭术和辅助化疗的标准方法治疗老年患者。存在以下情况的老年患者不适合手术,应考虑其他治疗方法:营养状况差(血清白蛋白<3.0 g/dL)、体能状态差(ASA≥3 级)和 IV 期疾病。这些因素中的一些可以通过治疗基础癌症来改变。这些患者应接受两到三个周期的新辅助化疗,并重新评估手术减瘤情况。如果患者的营养或体能状态得到改善,可以进行间隔性肿瘤细胞减灭术,目标是切除所有可见的肿瘤。

相似文献

1
Considerations in the surgical management of ovarian cancer in the elderly.老年卵巢癌的手术治疗考虑因素。
Curr Treat Options Oncol. 2013 Mar;14(1):12-21. doi: 10.1007/s11864-012-0216-2.
2
Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.对于晚期卵巢癌,仅新辅助化疗后的肿瘤完全切除比不完全减瘤更有益。
Eur J Obstet Gynecol Reprod Biol. 2017 Dec;219:100-105. doi: 10.1016/j.ejogrb.2017.10.019. Epub 2017 Oct 19.
3
Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.优化卵巢癌治疗:新辅助化疗和间隔肿瘤缩小术与初始肿瘤细胞减灭术治疗可能无法实现理想切除的上皮性卵巢癌。
Gynecol Oncol. 2017 Feb;144(2):266-273. doi: 10.1016/j.ygyno.2016.11.021. Epub 2016 Dec 1.
4
A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.术前低癌抗原125水平(≤25.8毫克/分升)是确定上皮性卵巢癌新辅助化疗后间歇性肿瘤细胞减灭术最佳时机的有用标准。
Jpn J Clin Oncol. 2016 Jun;46(6):517-21. doi: 10.1093/jjco/hyw029. Epub 2016 Mar 13.
5
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.新辅助化疗后延迟细胞减灭术治疗晚期上皮性卵巢癌的生存结局。
Int J Gynecol Cancer. 2020 Dec;30(12):1935-1942. doi: 10.1136/ijgc-2020-001658. Epub 2020 Oct 29.
6
Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.年龄校正的Charlson共病指数对晚期上皮性卵巢癌新辅助化疗后行肿瘤细胞减灭术患者围手术期并发症、辅助化疗使用情况及生存的预测价值。
J Obstet Gynaecol. 2017 Nov;37(8):1070-1075. doi: 10.1080/01443615.2017.1324413. Epub 2017 Jul 25.
7
Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.新辅助化疗使晚期卵巢癌的最佳减瘤率与直接手术相当,但不能提高生存率。
Arch Gynecol Obstet. 2013 Dec;288(6):1399-403. doi: 10.1007/s00404-013-2924-7. Epub 2013 Jun 18.
8
Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.接受初次肿瘤细胞减灭术及新辅助化疗-中间型肿瘤细胞减灭术治疗的卵巢癌患者的重症监护病房收治情况。
Gynecol Oncol. 2017 Dec;147(3):612-616. doi: 10.1016/j.ygyno.2017.09.028. Epub 2017 Oct 4.
9
Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?晚期上皮性卵巢癌的初次手术或间隔减瘤术:有关系吗?
Int J Gynecol Cancer. 2014 Oct;24(8):1420-8. doi: 10.1097/IGC.0000000000000241.
10
Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.新辅助化疗联合卡铂和紫杉醇治疗不适合初次手术的晚期卵巢癌患者:安全性和有效性。
Gynecol Oncol. 2014 Feb;132(2):287-91. doi: 10.1016/j.ygyno.2013.12.002. Epub 2013 Dec 9.

引用本文的文献

1
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.老年对接受化疗的晚期卵巢癌女性治疗结局的影响:NRG Oncology/Gynecologic Oncology Group(GOG-0182-ICON5)辅助研究。
Gynecol Oncol. 2023 Jun;173:130-137. doi: 10.1016/j.ygyno.2023.03.018. Epub 2023 May 4.
2
Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.每周给予紫杉醇和卡铂治疗体能状态差的晚期卵巢癌患者的疗效。
Int J Clin Oncol. 2018 Aug;23(4):698-706. doi: 10.1007/s10147-018-1264-9. Epub 2018 Mar 23.
3

本文引用的文献

1
The implications of age and comorbidity on survival following epithelial ovarian cancer: summary and results from a Centers for Disease Control and Prevention study.年龄和合并症对上皮性卵巢癌生存的影响:疾病控制和预防中心研究的总结和结果。
J Womens Health (Larchmt). 2012 Sep;21(9):887-94. doi: 10.1089/jwh.2012.3781. Epub 2012 Jul 20.
2
Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients.年龄和合并症对老年卵巢癌患者治疗方式、治疗依从性和预后的意义。
Gynecol Oncol. 2012 Nov;127(2):367-74. doi: 10.1016/j.ygyno.2012.07.001. Epub 2012 Jul 16.
3
Age is associated with prognosis in serous ovarian carcinoma.
年龄与浆液性卵巢癌的预后相关。
J Ovarian Res. 2017 Jun 12;10(1):36. doi: 10.1186/s13048-017-0331-6.
Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
根治性细胞减灭术治疗晚期卵巢癌时完全肿瘤细胞减灭术且无肉眼残留病灶对生存的影响。
Ann Surg Oncol. 2012 Dec;19(13):4059-67. doi: 10.1245/s10434-012-2446-8. Epub 2012 Jul 6.
4
Are the frail destined to fail? Frailty index as predictor of surgical morbidity and mortality in the elderly.虚弱的人注定会失败吗?虚弱指数预测老年人的手术发病率和死亡率。
J Trauma Acute Care Surg. 2012 Jun;72(6):1526-30; discussion 1530-1. doi: 10.1097/TA.0b013e3182542fab.
5
Splenectomy as part of primary cytoreductive surgery for advanced ovarian cancer: a retrospective cohort study.脾切除术作为高级卵巢癌初级细胞减灭术的一部分:一项回顾性队列研究。
Int J Gynecol Cancer. 2012 Jul;22(6):968-73. doi: 10.1097/IGC.0b013e3182571479.
6
Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).新辅助化疗(NACT)是治疗晚期卵巢癌(FIGO 分期 IIIC 和 IV 期)老年女性的有效方法。
J Surg Oncol. 2013 Feb;107(2):195-200. doi: 10.1002/jso.23171. Epub 2012 May 30.
7
Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes.直肠乙状结肠切除术在原发性细胞减灭术治疗晚期卵巢癌中的应用。一项多中心手术和肿瘤学结局分析。
Gynecol Oncol. 2012 Aug;126(2):220-3. doi: 10.1016/j.ygyno.2012.04.030. Epub 2012 Apr 30.
8
Predictors of critical care-related complications in colectomy patients using the National Surgical Quality Improvement Program: exploring frailty and aggressive laparoscopic approaches.利用国家手术质量改进计划预测结肠切除术患者的重症监护相关并发症:探讨脆弱性和积极的腹腔镜方法。
J Trauma Acute Care Surg. 2012 Apr;72(4):878-83. doi: 10.1097/TA.0b013e31824d0f70.
9
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).分析同期接受根治性手术(PDS)与新辅助化疗(NACT)随机 EORTC-NCIC 试验的大块晚期卵巢、输卵管和腹膜癌患者。
Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13.
10
Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization.老年女性行初次肿瘤细胞减灭术治疗卵巢癌的发病率、死亡率和总生存率:需要个体化的微妙平衡。
Gynecol Oncol. 2011 Nov;123(2):187-91. doi: 10.1016/j.ygyno.2011.06.031. Epub 2011 Jul 26.